Please assess the completion status of the following clinical trial:

Trial Title: Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven oesophageal squamous cell carcinoma or adenocarcinoma~* Both early stage and locally advanced tumor patients (according to TNM staging version 8):~* T1, N1-3, M0 after complete work-up~* T2, N0-3, M0 after complete work-up~* T3, N0-3, M0~* Patient eligible for definitive chemoradiation and not considered for primary surgery after multidisciplinary meeting decision or patient refuses to undergo surgery~* Subject must be previously untreated with systemic treatment given as primary therapy for advanced or metastatic disease~* At least one measurable lesion by CT scan or MRI based on RECIST version 1.1 with radiographic tumor assessment performed within 28 days prior to randomization~* Availability of adequate tissue in terms of quality and quantity for immunohistochemical staining for PDL-1~* WHO performance status 0 or 1~* Adequate organ function within 14 days prior to randomization~Exclusion Criteria:~* Cancer of cervical oesophagus (15 to 19 cm from dental ridge)~* Known Her2 positive adenocarcinoma~* Weight loss \> 15 % over the last 3 months without improvement after nutritional support~* Patient with cardiac dysfunction e.g. symptomatic congestive heart failure, uncontrolled hypertension~* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.~* Any prior treatment for advanced disease including treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.~* Live vaccines within 30 days prior to the first dose of study therapy. Examples of live vaccines include, but are not limited to the following: measles, mumps, rubella, chicken pox, yellow fever, H1N1 flu, rabies, BCG, and typhoid vaccine~* History of hypersensitivity to study drugs or any excipient (refer to SmPCs for ipilimumab, nivolumab, 5-FU and oxaliplatin)~* Current participation or treatment with an investigational agent or use of an investigational agent within 4 weeks of the first dose of study treatment~* Serious comorbidity or life expectancy less than one year~* Contraindication to chemoradiation therapy~* Treatment history of radiotherapy~* Child-Pugh B/C and patients with history of acute or chronic pancreatitis~* Patient with Type I diabetes mellitus, or skin disorders~* Known severe systemic autoimmune disease affecting the lungs or the bowel~* Known contraindication to CT scans with IV contrast~* Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 15 days prior to enrollment~* Active autoimmune disease that has required systemic treatment in past 2 years~* Autoimmune paraneoplastic syndrome requiring immunosuppressive or dedicated treatment~* History of any other hematologic or primary solid tumor malignancy, unless in remission for at least 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Chemoradiation + Nivolumab (Type: EXPERIMENTAL): All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
- Arm B: Chemoradiation + Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues